Dehydrolithocholic Acid (DHLCA) Ameliorates Diabetic Kidney Disease by Activating TGR5/FXR Signaling and Remodeling the Gut Microbiota
Pharmaceutical Sciences and Drug Design · 2022
DOI: 10.51847/2rlip6mpou ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutical Sciences and Drug Design, 2022. Verfasst von Liam Wilson und 2 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben.
Abstract (Originalsprache)
Diabetic kidney disease (DKD) is one of the primary causes of long-term loss of renal function internationally. In recent years, bile acids (BAs) have emerged as important metabolic signals influencing glucose control and kidney physiology. This project explored how disturbances in BA pathways contribute to DKD advancement. Plasma BA concentrations were quantified in healthy individuals (HC), subjects with type 2 diabetes mellitus (T2DM), and patients diagnosed with DKD using ultra-high-performa
Zitieren
APA
Wilson, L., Baker, N., & Turner, A. (2022). Dehydrolithocholic Acid (DHLCA) Ameliorates Diabetic Kidney Disease by Activating TGR5/FXR Signaling and Remodeling the Gut Microbiota. Pharmaceutical Sciences and Drug Design. https://doi.org/10.51847/2rlip6mpou
Vancouver
Wilson L, Baker N, Turner A. Dehydrolithocholic Acid (DHLCA) Ameliorates Diabetic Kidney Disease by Activating TGR5/FXR Signaling and Remodeling the Gut Microbiota. Pharmaceutical Sciences and Drug Design. 2022. doi:10.51847/2rlip6mpou
BibTeX
@article{Wilson2022,
author = {Wilson, Liam and Baker, Noah and Turner, Ava},
title = {Dehydrolithocholic Acid (DHLCA) Ameliorates Diabetic Kidney Disease by Activating TGR5/FXR Signaling and Remodeling the Gut Microbiota},
journal = {Pharmaceutical Sciences and Drug Design},
year = {2022},
doi = {10.51847/2rlip6mpou}
}
EUVIMED